Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model

Blood

Volumn 100, Issue 9, 2002, Pages 3361-3368

  Spurbeck, William W ^a   Ng, Catherine Y C ^b   Strom, Ted S ^b   Vanin, Elio F ^a   Davidoff, Andrew M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; CD31 ANTIGEN; GELATINASE A; MATRIX METALLOPROTEINASE; RETROVIRUS VECTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 3; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; AUTOCRINE EFFECT; BASEMENT MEMBRANE; CAPILLARY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; HEMOSTASIS; IMMUNOHISTOCHEMISTRY; MELANOMA CELL; METASTASIS; MORPHOGENESIS; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; SCID MOUSE; TUMOR GROWTH; TUMOR IMMUNOLOGY; VASCULAR ENDOTHELIUM;

EID: 0036839094     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.9.3361     Document Type: Article

References (59)

1. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992;3:65-71.
2. Bicknell R, Harris AL. Mechanisms and therapeutic implications of angiogenesis. Curr Opin Oncol. 1996;8:60-65.
3. Pluda JM. Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies. Semin Oncol. 1997;24:203-218.
4. Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol. 1992;3:89-96.
5. Bicknell R, Harris AL. Anticancer strategies involving the vasculature: Vascular targeting and the inhibition of angiogenesis. Semin Cancer Biol. 1992;3:399-407.
6. Scott PA, Harris AL. Current approaches to targeting cancer using antiangiogenesis therapies. Cancer Treat Rev. 1994;20:393-412.
7. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-674.
8. Bicknell R. Mechanistic insights into tumor angiogenesis. In: Bicknell R, Lewis CE, Napoleone F, eds. Tumor Angiogenesis. Oxford, United Kingdom: Oxford University Press; 1997:19-28.
9. Curran S, Murray GI. Matrix metalloproteinases: Molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000;36:1621-1630.
10. Gomez DE,Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74:111-122.
11. Blavier L, Henriet P, Imren S, DeClerck YA. Tissue inhibitors of matrix metalloproteinases in cancer. Ann NY Acad Sci. 1999;878:108-119.
12. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med. 1999;31:34-45.
13. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999;13:781-792.
14. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 1999;189:300-308.
15. Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer. 1999;79:1347-1355.
16. Ahonen M, Baker AH, Kahari VM. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res. 1998;58:2310-2315.
17. Anand-Apte B, Bao L, Smith R, et al. A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol. 1996;74:853-862.
18. Bian J, Wang Y, Smith MR, et al. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis.1996;17:1805-1811.
19. Anand-Apte B, Pepper MS, Voest E, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3 [see comments]. Invest Ophthalmol Vis Sci. 1997;38:817-823.
20. Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst. 1997;89:1586-1594.
21. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol. 1987;7:379-387.
22. Persons DA, Allay JA, Allay ER, et al. Enforced expression of the GATA-2 transcription factor blocks normal hematopoiesis. Blood. 1999;93:488-499.
23. Migita M, Medin JA, Pawliuk R, et al. Selection of transduced CD34+ progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectors. Proc Natl Acad Sci U S A. 1995;92:12075-12079.
24. Persons DA, Mehaffey MG, Kaleko M, Nienhuis AW, Vanin EF. An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene. Blood Cells Molecules Dis. 1998;24:167-182.
25. Yang Y, Vanin EF, Whitt MA, et al. Inducible, high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein. Hum Gene Ther. 1995;6:1203-1213.
26. Davidoff AM, Leary MA, Ng CYC, et al. Autocrine expression of both endostatin and green fluorescent protein provides a synergistic antitumor effect in a murine neuroblastoma model. Cancer Gene Therapy. 2001;8:537-545.
27. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
28. Lin P, Sankar S, Shan S, et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ. 1998;9:49-58.
29. Kubota Y, Kleinman HK, Martin GR, Lawley TJ. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol. 1988;107:1589-1598.
30. Grant DS, Tashiro K, Segui-Real B, Yamada Y, Martin GR, Kleinman HK. Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell. 1989;58:933-943.
31. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro: TIMP-3 promotes apoptosis. J Clin Invest. 1998;101:1478-1487.
32. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: Possible in vivo regulation via induction of proteases. Cancer Res. 2001;61:2145-2153.
33. Darland DC, D'Amore PA. Blood vessel maturation: Vascular development comes of age [comment]. J Clin Invest. 1999;103:157-158.
34. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-395.
35. Weidner N, Folkman J. Tumor vascularity as a prognostic factor in cancer, In: DeVita VT, Hellman S, Rosenberg S, eds. Cancer Principles and Practice. Philadelphia, PA: Lippincott-Raven; 1997:1-24.
36. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies. Cancer Res. 2000;60:1388-1393.
37. Springer ML, Ip TK, Blau HM. Angiogenesis monitored by perfusion with a space-filling microbead suspension. Mol Ther. 2000;1:82-87.
38. Shweiki D, Neeman M, ItinA, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis. Proc Natl Acad Sci U S A. 1995;92:768-772.
39. Shweiki D, Itin A, Softer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
40. Dejana E, Bazzoni G, Lampugnani MG. Vascular endothelial (VE)-cadherin: Only an intercellular glue? Exp Cell Res. 1999;252:13-19.
41. Gory-Faure S, Prandini MH, Pointu H, et al. Role of vascular endothelial-cadherin in vascular morphogenesis. Development. 1999;126:2093-2102.
42. Esser S, Lampugnani MG, Corada M, Dejana E, Risau W. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci. 1998;111:1853-1865.
43. Vittet D, Buchou T, Schweitzer A, Dejana E, Huber P. Targeted null-mutation in the vascular endothelial-cadherin gene impairs the organization of vascular-like structures in embryoid bodies. Proc Natl Acad Sci U S A. 1997;94:6273-6278.
44. Imren S, Kohn DB, Shimada H, Blavier L, DeClerck YA. Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res. 1996;56:2891-2895.
45. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 1992;52:701-708.
46. BenEzra D. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3 [letter; comment]. Invest Ophthalmol Vis Sci. 1997;38:2433-2434.
47. Brand K, Baker AH, Perez-Canto A, et al. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res. 2000;60:5723-5730.
48. Hajitou A, Sounni NE, Devy L, et al. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: Effect on in vivo mammary tumor growth and angiogenesis. Cancer Res. 2001;61:3450-3457.
49. Li H, Lindenmeyer F, Grenet C, et al. AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice. Hum Gene Ther. 2001;12:515-526.
50. Folkman J. Angiogenesis-dependent diseases. Semin Oncol. 2001;28:536-542.
51. Luzzi KJ, Varghese HJ, MacDonald IC, et al. Inhibition of angiogenesis in liver metastases by carboxyamidotriazole (CAI). Angiogenesis. 1998;2:373-378.
52. Bond M, Murphy G, Bennett MR, et al. Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus: Metalloproteinase inhibition is associated with proapoptotic activity. J Biol Chem. 2000;275:41358-41363.
53. George SJ, Lloyd CT, Angelini GD, Newby AC, Baker AH. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation. 2000;101:296-304.
54. Pettersson A, Nagy JA, Brown LF, et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest. 2000;80:99-115.
55. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: Deleterious effects of unregulated expression, Circulation. 2000;102:898-901.
56. Carmeliet P. VEGF gene therapy: Stimulating angiogenesis or angioma-genesis? Nat Med. 2000;6:1102-1103.
57. Springer ML, Chen A, Kraft PE, Bednarski M, Blau HM. VEGF gene delivery to muscle: Potential role for vasculogenesis in adults. Mol Cell. 1998;2:549-558.
58. Yamagishi S, Yonekura H, Yamamoto Y, et al. Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions. Lab Invest. 1999;79:501-509.
59. Hellstrom M, Gerhardt H, Kalen M, et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol. 2001;153:543-553.